ArticleFrontiers in pharmacology2026
Tanshinone IIA inhibits malignant progression in a spontaneous breast cancer mouse model by attenuating tissue factor-mediated angiogenesis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As a classic botanical drug, Methods: We adopted the mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT) transgenic mouse model, which recapitulates the natural progression of spontaneous breast tumorigenesis. A combination of pharmacokinetic analysis, network pharmacology, Results: Our results demonstrated that Tan IIA markedly delayed the malignant transformation of benign mammary tumors. Pharmacokinetic characterization confirmed the favorable Discussion: Our work reveals that Tan IIA exerts prominent chemopreventive effects against breast precancerous lesions, mainly by suppressing TF-mediated angiogenesis, indicating its great promise as a candidate agent for early breast cancer intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.